A Phase 3, Randomized, Multi-center, Active-controlled, Open-label Study to Evaluate the Efficacy and Safety of Peginterferon Alfa-2b (40kD, Y Shape) in Chinese Chronic Hepatitis B Patients.
Phase of Trial: Phase III
Latest Information Update: 03 Sep 2015
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Peginterferon alfa-2a
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Xiamen Amoytop Biotech
- 28 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 29 Nov 2013 Planned End Date changed from 1 Jan 2016 to 1 Dec 2015 as reported by ClinicalTrials.gov.